Stock Financial Ratios, Dividends, Split History

NVLN / NOVELION THERAPEUTICS INC. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)71.07
Book Value ($M)14.94
Book Value / Share0.80
Price / Book4.76
NCAV ($M)-249.44
NCAV / Share-13.34
Price / NCAV-0.27
Share Statistics
Common Shares Outstanding 18,703,204
Common Stock Shares Outstanding 18,702,000
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-8.48
Return on Assets (ROA)-0.26
Return on Equity (ROE)-0.93
Balance Sheet (mrq) ($M)
Quick Ratio1.39
Current Ratio1.63
Income Statement (mra) ($M)
Sales Revenue Goods Net138,438,000.00
Operating Income-86.80
Net Income-126.70
Earnings Per Share Basic And Diluted-6.81
Cash Flow Statement (mra) ($M)
Cash From Operations-54.90
Cash from Investing-0.75
Cash from Financing-0.75
Identifiers and Descriptors
Central Index Key (CIK)827809
Related CUSIPS
67001K902 67001K202 67001K103 67001K952

Split History

Stock splits are used by NOVELION THERAPEUTICS INC. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Biotech Leadership Transformations: Week of June 11th

2018-06-18 biospace
Biotech companies continue to make moves to strengthen senior leadership teams and drive growth. Below is a roundup of some noted movers and shakers for the week of June 11 - 15. (162-2)

Your Daily Pharma Scoop: ScPharma Slumps, Sellas Surges And Zymeworks Trading Suspended

2018-06-02 seekingalpha
ScPharma (NASDAQ:SCPH) was part of almost every stock news column (including ours) yesterday for its massive slump of ~30% in a single day. Today we come back to focus our discussion on the stock while the slide continues further. Yesterday it touched its 52 wk low at $8.5, but recovered a little and closed marginally higher at $8.92. Cumulatively, over the last few days the company slid from $14.22 to $8. (209-4)

Former Aegerion sales rep charged with defrauding U.S. insurers

2018-05-15 reuters
NEW YORK, May 15 (Reuters) - A former Aegerion Pharmaceuticals Inc sales representative was arrested Tuesday on charges that he defrauded insurance companies into paying for the company’s expensive cholesterol drug. (11-1)

BRIEF-Novelion Therapeutics Says Its Unit Has Entered Into A New Secured Financing Facility

2018-03-15 reuters

CUSIP: 746927102